Arctoris

Executive Summary

Arctoris is a UK-based Partnership Research Organisation (PRO) that accelerates drug discovery through its automated wet lab biology R&D and data generation services. Founded in 2016 and headquartered in Oxford, the company combines robotics, data science, and biological expertise to produce precise, reproducible, and AI-ready experimental data for biotech, techbio, and pharma partners. Its core technology, the Ulysses® platform, is a fully robotic, cloud-controlled discovery system that enables high-throughput, standardized experimentation. By offering contract research services with integrated machine learning capabilities, Arctoris aims to reduce the time and cost of early-stage drug development while improving data quality. The company operates at the intersection of drug delivery and AI/machine learning, positioning itself as a key enabler for partners seeking to leverage automation and data-driven insights in their R&D pipelines. With no disclosed funding or valuation, Arctoris remains a private entity focused on scaling its partnership model and expanding its client base. Arctoris's value proposition lies in its ability to generate high-quality, reproducible data that is readily usable for AI model training, addressing a critical bottleneck in AI-driven drug discovery. The company's robotic platform minimizes human error and variability, offering a significant advantage over traditional CROs. As the demand for automated, AI-ready experimental data grows, Arctoris is well-positioned to capture market share. However, the company faces competition from other automated biology platforms and contract research organizations. Its success will depend on securing major partnerships and achieving operational scale. Overall, Arctoris represents a promising, though capital-intensive, venture in the evolving landscape of tech-enabled drug discovery.

Upcoming Catalysts (preview)

• Q3 2026Major pharma partnership for Ulysses platform deployment60% success
• Q4 2026Series A funding round to scale operations70% success
• Q2 2027Launch of expanded service offerings for AI-ready data generation80% success